Cargando…
Histological Subtypes Drive Distinct Prognostic Immune Signatures in Classical Hodgkin Lymphoma
SIMPLE SUMMARY: Classical Hodgkin lymphoma (cHL) is a highly curable disease, with about 80% of patients cured using standard first-line chemotherapy. However, outcomes for relapsed/refractory patients remain unfavorable and there is a critical lack of predictive biomarkers for early identification...
Autores principales: | Lamaison, Claire, Ferrant, Juliette, Gravelle, Pauline, Traverse-Glehen, Alexandra, Ghesquières, Hervé, Tosolini, Marie, Rossi, Cédric, Ysebaert, Loic, Brousset, Pierre, Laurent, Camille, Syrykh, Charlotte |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9563296/ https://www.ncbi.nlm.nih.gov/pubmed/36230815 http://dx.doi.org/10.3390/cancers14194893 |
Ejemplares similares
-
Plasticity in Classical Hodgkin Composite Lymphomas: A Systematic Review
por: Trecourt, Alexis, et al.
Publicado: (2022) -
Several immune escape patterns in non-Hodgkin's lymphomas
por: Laurent, Camille, et al.
Publicado: (2015) -
Profiling Immune Escape in Hodgkin’s and Diffuse large B-Cell Lymphomas Using the Transcriptome and Immunostaining
por: Péricart, Sarah, et al.
Publicado: (2018) -
Mechanisms of PD-1/PD-L1 expression and prognostic relevance in non-Hodgkin lymphoma: a summary of immunohistochemical studies
por: Gravelle, Pauline, et al.
Publicado: (2017) -
Epstein–Barr Virus-Associated T- and NK-Cell Lymphoproliferative Diseases: A Review of Clinical and Pathological Features
por: Syrykh, Charlotte, et al.
Publicado: (2021)